Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | PPIA | P62937 | 5/20 | 0.59 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297414 | 0.88 | BRD4 (0.74) | BRD4TDP1L3MBTL1PPIASGMS2 | |
| SCHEMBL26669004 | 0.87 | BRD4 (0.60) | BRD4TDP1L3MBTL1PPIASGMS2 | |
| SCHEMBL8924076 | 0.87 | BRD4 (1.00) | BRD4TDP1L3MBTL1PPIARAB9A | |
| SCHEMBL11549645 | 0.85 | BRD4 (0.70) | BRD4TDP1L3MBTL1PPIASGMS2 | |
| SCHEMBL38660185 | 0.85 | BRD4 (0.70) | BRD4TDP1L3MBTL1PPIASGMS2 | |
| SCHEMBL7298832 | 0.85 | BRD4 (0.70) | BRD4TDP1L3MBTL1PPIASGMS2 | |
| SCHEMBL5174575 | 0.84 | BRD4 (0.68) | BRD4TDP1L3MBTL1PPIASGMS2 | |
| SCHEMBL21810510 | 0.84 | PPIA (0.76) | BRD4TDP1L3MBTL1PPIASGMS2 | |
| SCHEMBL13652590 | 0.84 | BRD4 (0.73) | BRD4TDP1L3MBTL1PPIASGMS2 | |
| SCHEMBL7935581 | 0.84 | BRD4 (0.68) | BRD4TDP1L3MBTL1PPIASGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349858-B1 | AGENTS USEFUL FOR REDUCING AMYLOID PRECURSOR PROTEIN AND TREATING DEMANTIA AND METHODS OF USE THEREOF | US GOV HEALTH & HUMAN SERV (US) | 2008-08-27 | — | — | EP | claimed |
| US-7153882-B2 | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-12-26 | — | — | US | claimed |
| US-9487507-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-08 | — | — | US | disclosed |
| EP-2720546-B1 | SPIRO-CYCLIC TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20140113916-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2720546-A1 | TRPV4 ANTAGONISTS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174342-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20100099690-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-04-22 | — | — | US | disclosed |
| EP-1912993-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017265-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-0525197-B1 | 3-BENZYLIDENE-1-CARBAMOYL-2-PYRROLIDONE ANALOGS | SHIONOGI & CO (JP) | 1997-08-27 | — | — | EP | disclosed |
| US-5319100-A | Antiinflammatory agent which does not cause stomach diseases | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-06-07 | — | — | US | disclosed |
| US-5319099-A | Antiinflammatory agent which does not cause stomach diseases | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-06-07 | — | — | US | disclosed |
| EP-0525197-A1 | 3-BENZYLIDENE-1-CARBAMOYL-2-PYRROLIDONE ANALOG | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113916-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV3, TRPV5 | BRD4 343/4885TDP1 4249/4885L3MBTL1 4181/4885 |
| US-20100099690-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, HCAR1 | BRD4 3083/4885TDP1 966/4885L3MBTL1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.